{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T09:58:11Z","timestamp":1775123891643,"version":"3.50.1"},"reference-count":45,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T00:00:00Z","timestamp":1619481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Dengue virus (DENV) is a flavivirus associated with clinical manifestations ranging in severity from self-limiting dengue fever, to the potentially life threatening condition, severe dengue. There are currently no approved antiviral therapies for the treatment of DENV. Here, we evaluated the antiviral potential of four broad-spectrum antivirals, UV-4B, interferon-alpha (IFN), sofosbuvir (SOF), and favipiravir (FAV) against DENV serotype 2 as mono- and combination therapy in cell lines that are physiologically relevant to human infection. Cell lines derived from human liver (HUH-7), neurons (SK-N-MC), and skin (HFF-1) were infected with DENV and treated with UV-4B, IFN, SOF, or FAV. Viral supernatant was sampled daily and infectious viral burden was quantified by plaque assay on Vero cells. Drug effect on cell proliferation in uninfected and infected cells was also assessed. UV-4B inhibited DENV in HUH-7, SK-N-MC, and HFF-1 cells yielding EC50 values of 23.75, 49.44, and 37.38 \u00b5M, respectively. Clinically achievable IFN concentrations substantially reduced viral burden in HUH-7 (EC50 = 102.7 IU\/mL), SK-N-MC (EC50 = 86.59 IU\/mL), and HFF-1 (EC50 = 163.1 IU\/mL) cells. SOF potently inhibited DENV in HUH-7 cells but failed to produce the same effect in SK-N-MC and HFF-1 cells. Finally, FAV provided minimal suppression in HUH-7 and SK-N-MC cells, but was ineffective in HFF-1 cells. The two most potent anti-DENV agents, UV-4B and IFN, were also assessed in combination. UV-4B + IFN treatment enhanced antiviral activity in HUH-7, SK-N-MC, and HFF-1 cells relative to monotherapy. Our results demonstrate the antiviral potential of UV-4B and IFN against DENV in multiple physiologically relevant cell types.<\/jats:p>","DOI":"10.3390\/v13050771","type":"journal-article","created":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T21:18:20Z","timestamp":1619558300000},"page":"771","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Antiviral Evaluation of UV-4B and Interferon-Alpha Combination Regimens against Dengue Virus"],"prefix":"10.3390","volume":"13","author":[{"given":"Evelyn J.","family":"Franco","sequence":"first","affiliation":[{"name":"Institute for Therapeutic Innovation, Department of Medicine, College of Medicine, University of Florida, Orlando, FL 32827, USA"},{"name":"Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, FL 32827, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilly P.","family":"Pires de Mello","sequence":"additional","affiliation":[{"name":"Institute for Therapeutic Innovation, Department of Medicine, College of Medicine, University of Florida, Orlando, FL 32827, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9993-5241","authenticated-orcid":false,"given":"Ashley N.","family":"Brown","sequence":"additional","affiliation":[{"name":"Institute for Therapeutic Innovation, Department of Medicine, College of Medicine, University of Florida, Orlando, FL 32827, USA"},{"name":"Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, FL 32827, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,4,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Back, A.T., and Lundkvist, A. (2013). Dengue viruses\u2014An overview. Infect. Ecol. Epidemiol., 3.","DOI":"10.3402\/iee.v3i0.19839"},{"key":"ref_2","unstructured":"Centers for Disease Control and Prevention (2020, December 19). About Dengue: What You Need to Know, Available online: https:\/\/www.cdc.gov\/dengue\/about\/index.html."},{"key":"ref_3","unstructured":"World Health Organization (2020, December 19). Dengue and Severe Dengue. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dengue-and-severe-dengue."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1093\/infdis\/jiw649","article-title":"Clinical and Laboratory Diagnosis of Dengue Virus Infection","volume":"215","author":"Muller","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4103\/0972-2327.144306","article-title":"\u201cDot sign\u201d in dengue encephalitis","volume":"18","author":"Mathew","year":"2015","journal-title":"Ann. Indian Acad. Neurol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Garg, R.K., Rizvi, I., Ingole, R., Jain, A., Malhotra, H.S., Kumar, N., and Batra, D. (2017). Cortical laminar necrosis in dengue encephalitis-a case report. BMC Neurol., 17.","DOI":"10.1186\/s12883-017-0855-9"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jns.2011.01.012","article-title":"Review of the etiologies of viral meningitis and encephalitis in a dengue endemic region","volume":"303","author":"Soares","year":"2011","journal-title":"J. Neurol. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/jns.12190","article-title":"Asymptomatic dengue infection may trigger Guillain-Barre syndrome","volume":"21","author":"Umapathi","year":"2016","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3389\/fcimb.2017.00449","article-title":"Neurological Manifestations of Dengue Infection","volume":"7","author":"Li","year":"2017","journal-title":"Front. Cell Infect. Microbiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1080\/21645515.2019.1658503","article-title":"A review of Dengvaxia(R): Development to deployment","volume":"15","author":"Thomas","year":"2019","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"World Health Organization (2018). Dengue Vaccine: WHO position paper\u2014September 2018. Wkly. Epidemiol. Rec., 36, 457\u2013476.","DOI":"10.1016\/j.vaccine.2018.03.009"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5592","DOI":"10.1128\/JVI.00028-15","article-title":"Dengue Virus Evolution under a Host-Targeted Antiviral","volume":"89","author":"Plummer","year":"2015","journal-title":"J. Virol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"7484","DOI":"10.1038\/s41598-019-43030-y","article-title":"Lack of selective resistance of influenza A virus in presence of host-targeted antiviral, UV-4B","volume":"9","author":"Warfield","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/978-981-10-8727-1_20","article-title":"Mechanisms of Antiviral Activity of Iminosugars Against Dengue Virus","volume":"1062","author":"Miller","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.antiviral.2016.03.001","article-title":"Inhibition of endoplasmic reticulum glucosidases is required for in vitro and in vivo dengue antiviral activity by the iminosugar UV-4","volume":"129","author":"Warfield","year":"2016","journal-title":"Antivir. Res."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Warfield, K.L., Barnard, D.L., Enterlein, S.G., Smee, D.F., Khaliq, M., Sampath, A., Callahan, M.V., Ramstedt, U., and Day, C.W. (2016). The Iminosugar UV-4 is a Broad Inhibitor of Influenza A and B Viruses ex Vivo and in Mice. Viruses, 8.","DOI":"10.3390\/v8030071"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.cytogfr.2014.07.015","article-title":"Interferons: Success in anti-viral immunotherapy","volume":"25","author":"Lin","year":"2014","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature04082","article-title":"Mechanism of action of interferon and ribavirin in treatment of hepatitis C","volume":"436","author":"Feld","year":"2005","journal-title":"Nature"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nrd2422","article-title":"Interferons at age 50: Past, current and future impact on biomedicine","volume":"6","author":"Borden","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1006\/viro.2001.1114","article-title":"Interferon inhibits dengue virus infection by preventing translation of viral RNA through a PKR-independent mechanism","volume":"289","author":"Diamond","year":"2001","journal-title":"Virology"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Pires de Mello, C.P., Tao, X., Kim, T.H., Vicchiarelli, M., Bulitta, J.B., Kaushik, A., and Brown, A.N. (2018). Clinical Regimens of Favipiravir Inhibit Zika Virus Replication in the Hollow-Fiber Infection Model. Antimicrob. Agents Chemother., 62.","DOI":"10.1128\/AAC.00967-18"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Pires de Mello, C.P., Drusano, G.L., Rodriquez, J.L., Kaushik, A., and Brown, A.N. (2018). Antiviral Effects of Clinically-Relevant Interferon-alpha and Ribavirin Regimens against Dengue Virus in the Hollow Fiber Infection Model (HFIM). Viruses, 10.","DOI":"10.3390\/v10060317"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s12072-014-9606-9","article-title":"Sofosbuvir for treatment of chronic hepatitis C","volume":"9","author":"Kattakuzhy","year":"2015","journal-title":"Hepatol. Int."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"6345","DOI":"10.1038\/s41598-017-06612-2","article-title":"Evaluation of Sofosbuvir (beta-D-2\u2032-deoxy-2\u2032-alpha-fluoro-2\u2032-beta-C-methyluridine) as an inhibitor of Dengue virus replication","volume":"7","author":"Xu","year":"2017","journal-title":"Sci Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"40920","DOI":"10.1038\/srep40920","article-title":"The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication","volume":"7","author":"Sacramento","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.antiviral.2016.11.023","article-title":"The FDA-approved drug sofosbuvir inhibits Zika virus infection","volume":"137","author":"Govero","year":"2017","journal-title":"Antivir. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","article-title":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor","volume":"100","author":"Furuta","year":"2013","journal-title":"Antivir. Res."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Sissoko, D., Laouenan, C., Folkesson, E., M\u2019Lebing, A.B., Beavogui, A.H., Baize, S., Camara, A.M., Maes, P., Shepherd, S., and Danel, C. (2016). Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. PLoS Med., 13.","DOI":"10.1371\/journal.pmed.1002066"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2040206618807580","DOI":"10.1177\/2040206618807580","article-title":"The effectiveness of antiviral agents with broad-spectrum activity against chikungunya virus varies between host cell lines","volume":"26","author":"Franco","year":"2018","journal-title":"Antivir. Chem. Chemother."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Franco, E.J., Tao, X., Hanrahan, K.C., Zhou, J., Bulitta, J.B., and Brown, A.N. (2021). Combination Regimens of Favipiravir Plus Interferon Alpha Inhibit Chikungunya Virus Replication in Clinically Relevant Human Cell Lines. Microorganisms, 9.","DOI":"10.3390\/microorganisms9020307"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Begum, F., Das, S., Mukherjee, D., Mal, S., and Ray, U. (2019). Insight into the Tropism of Dengue Virus in Humans. Viruses, 11.","DOI":"10.3390\/v11121136"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s004280000329","article-title":"Liver histopathology and biological correlates in five cases of fatal dengue fever in Vietnamese children","volume":"438","author":"Huerre","year":"2001","journal-title":"Virchows Archiv"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.3389\/fmicb.2019.01435","article-title":"Dengue Virus Infection of Blood-Brain Barrier Cells: Consequences of Severe Disease","volume":"10","author":"Beltran","year":"2019","journal-title":"Front. Microbiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1093\/infdis\/jiw358","article-title":"Chikungunya Virus: In Vitro Response to Combination Therapy with Ribavirin and Interferon Alfa 2a","volume":"214","author":"Gallegos","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.antiviral.2013.06.011","article-title":"Antiviral therapies targeting host ER alpha-glucosidases: Current status and future directions","volume":"99","author":"Chang","year":"2013","journal-title":"Antivir. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.bbagen.2019.05.012","article-title":"Exploitation of glycosylation in enveloped virus pathobiology","volume":"1863","author":"Watanabe","year":"2019","journal-title":"Biochim. Biophys. Acta (BBA) Gen. Subj."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"104881","DOI":"10.1016\/j.antiviral.2020.104881","article-title":"Iminosugars: A host-targeted approach to combat Flaviviridae infections","volume":"184","author":"Starr","year":"2020","journal-title":"Antivir. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"549","DOI":"10.7326\/0003-4819-96-5-549","article-title":"Recombinant leukocyte A interferon: Pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients","volume":"96","author":"Gutterman","year":"1982","journal-title":"Ann. Intern. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/CMR.00102-15","article-title":"Approved Antiviral Drugs over the Past 50 Years","volume":"29","author":"Li","year":"2016","journal-title":"Clin. Microbiol Rev."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1128\/MCB.01808-08","article-title":"Receptor density is key to the alpha2\/beta interferon differential activities","volume":"29","author":"Moraga","year":"2009","journal-title":"Mol. Cell. Biol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"7202","DOI":"10.1021\/jm100863x","article-title":"Discovery of a beta-d-2\u2032-deoxy-2\u2032-alpha-fluoro-2\u2032-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus","volume":"53","author":"Sofia","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/cbdd.13091","article-title":"Sofosbuvir as treatment against dengue?","volume":"91","author":"Gan","year":"2018","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.antiviral.2017.09.004","article-title":"Cell-line dependent antiviral activity of sofosbuvir against Zika virus","volume":"146","author":"Mumtaz","year":"2017","journal-title":"Antivir. Res."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Jin, Z., Smith, L.K., Rajwanshi, V.K., Kim, B., and Deval, J. (2013). The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5\u2032-triphosphate towards influenza A virus polymerase. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0068347"},{"key":"ref_45","unstructured":"National Library of Medicine (U.S.) (12 February 2014\u201326 October 2016) (2021, January 02). Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT02061358."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/5\/771\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:53:23Z","timestamp":1760162003000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/5\/771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,27]]},"references-count":45,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,5]]}},"alternative-id":["v13050771"],"URL":"https:\/\/doi.org\/10.3390\/v13050771","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,27]]}}}